muraglitazar + insulin

This is a **combination therapy** of **muraglitazar**, a dual peroxisome proliferator-activated receptor (PPAR) agonist, and **insulin**, a therapy for glycemic control. Muraglitazar is a small molecule developed for type 2 diabetes, acting as both a PPARα and PPARγ agonist, thereby improving glycemic control, insulin sensitivity, and lipid profiles. Insulin is a peptide hormone essential for glucose metabolism. While muraglitazar has demonstrated benefits in A1C and lipid profile improvement, insulin is a foundational therapy for type 1 and type 2 diabetes mellitus with insufficient endogenous insulin production. Combination of muraglitazar with insulin is not well studied, and no evidence exists for a specific branded or marketed combination of these agents[1][2][3][4].